Hims & Hers Health/$HIMS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Hims & Hers Health
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Ticker
$HIMS
Sector
Primary listing
NYSE
Employees
1,637
Headquarters
Website
HIMS Metrics
BasicAdvanced
$10B
56.61
$0.78
2.14
-
Price and volume
Market cap
$10B
Beta
2.14
52-week high
$72.98
52-week low
$19.15
Average daily volume
27M
Financial strength
Current ratio
4.979
Quick ratio
4.205
Long term debt to equity
185.047
Total debt to equity
185.604
Interest coverage (TTM)
112.13%
Profitability
EBITDA (TTM)
160.154
Gross margin (TTM)
76.20%
Net profit margin (TTM)
9.62%
Operating margin (TTM)
6.50%
Effective tax rate (TTM)
-39.05%
Revenue per employee (TTM)
$1,230,000
Management effectiveness
Return on assets (TTM)
6.95%
Return on equity (TTM)
41.88%
Valuation
Price to earnings (TTM)
56.612
Price to revenue (TTM)
4.861
Price to book
17.81
Price to tangible book (TTM)
24.79
Price to free cash flow (TTM)
81.91
Free cash flow yield (TTM)
1.22%
Free cash flow per share (TTM)
0.542
Growth
Revenue change (TTM)
88.69%
Earnings per share change (TTM)
860.45%
3-year revenue growth (CAGR)
75.30%
3-year earnings per share growth (CAGR)
24.29%
What the Analysts think about HIMS
Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.
Bulls say / Bears say
In Q1 2025, revenue jumped 111% year-over-year to $586 million, driven by robust demand for its telehealth platform. (Reuters)
The acquisition of UK telehealth provider Zava broadens Hims & Hers’ reach into Germany, France, and Ireland, supporting its international growth ambitions. (Reuters)
Management revealed 2030 targets for at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA, signaling confidence in its long-term profitability outlook. (Barron’s)
FDA ban on compounded semaglutide disrupted Hims & Hers’ weight-loss offerings and led to a 4% workforce reduction, highlighting regulatory risk in its growth strategy. (Reuters)
The company’s Q2 2025 revenue guidance of $530 million to $550 million missed Street expectations of around $564 million, unsettling investors and pointing to possible short-term growth slowdown. (Barron’s)
Hims & Hers stock fell roughly 12% after posting Q2 sales of $544.8 million, which came in below analyst projections of $551.7 million, exposing its susceptibility to both execution and expectations misses. (Barron’s)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
HIMS Financial Performance
Revenues and expenses
HIMS Earnings Performance
Company profitability
HIMS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hims & Hers Health stock?
Hims & Hers Health (HIMS) has a market cap of $10B as of November 04, 2025.
What is the P/E ratio for Hims & Hers Health stock?
The price to earnings (P/E) ratio for Hims & Hers Health (HIMS) stock is 56.61 as of November 04, 2025.
Does Hims & Hers Health stock pay dividends?
No, Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Hims & Hers Health dividend payment date?
Hims & Hers Health (HIMS) stock does not pay dividends to its shareholders.
What is the beta indicator for Hims & Hers Health?
Hims & Hers Health (HIMS) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.